Subtype
Uterine Corpus Neoplasm
CI-CAN-00007035Explore in graph →
Non-malignant451 active trials4 approved drugs28 evidence items
- NCIt
- C6300
Loading cancer entity…
Subtype
CI-CAN-00007035Explore in graph →
Clinical trials
1,714 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00238121 | Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer | completed | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 2 | Nov 20, 2015 | clinicaltrials |
| NCT00057863 | Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Nov 17, 2015 | clinicaltrials |
| NCT01026792 | Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery | completed | Phase 2 | 38 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2015 | clinicaltrials |
| NCT00739830 | Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6) | completed | Phase 2 | 130 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 1, 2015 | clinicaltrials |
| NCT00217633 | Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer | completed | Phase 2 | 38 | Gynecologic Oncology GroupNETWORK | 2 | May 29, 2015 | clinicaltrials |
| NCT01379534 | A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer | completed | Phase 2 | 53 | Novartis PharmaceuticalsINDUSTRY | 7 | May 20, 2015 | clinicaltrials |
| NCT00072176 | Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer | completed | Phase 2 | 62 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2015 | clinicaltrials |
| NCT00122343 | AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED) | completed | Phase 2 | 45 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 19, 2015 | clinicaltrials |
| NCT00389974 | Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Feb 16, 2015 | clinicaltrials |
| NCT00507741 | Study of Vintafolide (MK-8109, EC145) in Participants With Advanced Ovarian and Endometrial Cancers (MK-8109-007, EC-FV-02) | completed | Phase 2 | 49 | EndocyteINDUSTRY | 0 | Jan 7, 2015 | clinicaltrials |
| NCT00388154 | Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer | completed | Phase 2 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 13, 2014 | clinicaltrials |
| NCT00870337 | Everolimus in Treating Patients With Relapsed or Metastatic Endometrial Cancer(ENDORAD) | completed | Phase 2 | 44 | ARCAGY/ GINECO GROUPOTHER | 1 | Oct 29, 2014 | clinicaltrials |
| NCT00886873 | Mifepristone 10 or 5 mg for 6 Months to Treat Uterine Fibroids(Mifemyo_2) | completed | Phase 2 / Phase 3 | 100 | Mediterranea Medica S. L.OTHER | 1 | Oct 17, 2014 | clinicaltrials |
| NCT01451424 | Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids | completed | Phase 2 | 40 | Repros Therapeutics Inc.INDUSTRY | 1 | Aug 29, 2014 | clinicaltrials |
| NCT00882258 | Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids | completed | Phase 2 | 144 | Repros Therapeutics Inc.INDUSTRY | 1 | Jul 8, 2014 | clinicaltrials |
| NCT00515073 | Papillary Serous Carcinoma of the Endometrium | completed | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 3, 2014 | clinicaltrials |
| NCT00245102 | Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma | completed | Phase 2 | 147 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT01631903 | Extension of Study ZPV-200 | completed | Phase 2 | 48 | Repros Therapeutics Inc.INDUSTRY | 1 | Apr 16, 2014 | clinicaltrials |
| NCT01739621 | Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids Who Have Completed ZPV-200 | completed | Phase 2 | 40 | Repros Therapeutics Inc.INDUSTRY | 0 | Apr 16, 2014 | clinicaltrials |
| NCT00087100 | Pemetrexed Disodium in Treating Patients With Persistent or Recurrent Endometrial Cancer | completed | Phase 2 | 51 | Gynecologic Oncology GroupNETWORK | 1 | Feb 14, 2014 | clinicaltrials |
| NCT00030485 | Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial Cancer | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Jan 27, 2014 | clinicaltrials |
| NCT00085332 | Docetaxel in Treating Patients With Recurrent or Persistent Endometrial Carcinoma (Cancer) | completed | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 5 | Jan 13, 2014 | clinicaltrials |
| NCT01079832 | Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies | completed | Phase 2 | 50 | Case Comprehensive Cancer CenterOTHER | 1 | Nov 28, 2013 | clinicaltrials |
| NCT01965080 | Exemestane in Advanced and Recurrent Endometrial Carcinoma | completed | Phase 2 | 52 | Nordic Society of Gynaecological Oncology - Clinical Trials UnitOTHER | 1 | Oct 18, 2013 | clinicaltrials |
| NCT00526149 | BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors | completed | Phase 2 | 76 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Oct 7, 2013 | clinicaltrials |
| NCT00023894 | Flavopiridol in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 5 | Jun 24, 2013 | clinicaltrials |
| NCT00071929 | Oxaliplatin in Treating Patients With Persistent or Recurrent Endometrial Cancer | completed | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 1 | Jun 24, 2013 | clinicaltrials |
| NCT00006005 | Thalidomide in Treating Patients With Gynecologic Sarcomas | completed | Phase 2 | — | New York University Cancer InstituteOTHER | 1 | Jun 21, 2013 | clinicaltrials |
| NCT00019331 | Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Jun 20, 2013 | clinicaltrials |
| NCT00006377 | Doxorubicin, Paclitaxel, and Carboplatin in Treating Patients With Primary Stage III, Stage IV, or Recurrent Endometrial Cancer | completed | Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 18, 2013 | clinicaltrials |
| NCT00003946 | Danazol in Treating Patients With Advanced or Recurrent Endometrial Cancer | completed | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 2 | Jun 10, 2013 | clinicaltrials |
| NCT00005643 | Chemotherapy in Treating Patients With Sarcoma of the Uterus | completed | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 2 | Jun 10, 2013 | clinicaltrials |
| NCT00005861 | Liposomal Doxorubicin in Treating Patients With Advanced or Recurrent Endometrial Cancer | completed | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 1 | Jun 10, 2013 | clinicaltrials |
| NCT00005031 | Irofulven in Treating Patients With Persistent or Recurrent, Refractory Endometrial Cancer | completed | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 2 | May 27, 2013 | clinicaltrials |
| NCT00033358 | Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer | completed | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | May 3, 2013 | clinicaltrials |
| NCT00025467 | Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT01452659 | Efficacy and Safety of TAK-385 in the Treatment of Uterine Fibroids | completed | Phase 2 | 216 | TakedaINDUSTRY | 1 | Jan 21, 2013 | clinicaltrials |
| NCT00107445 | EF5 in Finding Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Cervical, Endometrial, or Ovarian Epithelial Cancer | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00050440 | Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma | completed | Phase 2 | 50 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 4 | Jan 8, 2013 | clinicaltrials |
| NCT00881140 | Efficacy Study of Vaginal Mifepristone to Treat Uterine Fibroids | completed | Phase 2 | 30 | BioPro Medical LtdINDUSTRY | 1 | Dec 19, 2012 | clinicaltrials |
| NCT00837161 | Pilot Study of MRI-Guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids | completed | Phase 1 / Phase 2 | 11 | Philips HealthcareINDUSTRY | 1 | Dec 4, 2012 | clinicaltrials |
| NCT00003939 | Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma | completed | Phase 2 | 132 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Sep 24, 2012 | clinicaltrials |
| NCT00006357 | STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma | completed | Phase 1 / Phase 2 | 91 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 5 | Sep 24, 2012 | clinicaltrials |
| NCT00022620 | Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer | completed | Phase 2 | — | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | Sep 24, 2012 | clinicaltrials |
| NCT00052312 | Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer | completed | Phase 2 | 141 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 8 | Sep 24, 2012 | clinicaltrials |
| NCT00392769 | Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer | completed | Phase 2 | 33 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 6, 2012 | clinicaltrials |
| NCT00334295 | Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma. | completed | Phase 2 | 35 | AstraZenecaINDUSTRY | 1 | Jul 31, 2012 | clinicaltrials |
| NCT00505739 | Mifepristone for Patients With Endometrial Cancer and LGESS | completed | Phase 2 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2012 | clinicaltrials |
| NCT00267488 | Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial Cancer | completed | Phase 2 | 70 | GlaxoSmithKlineINDUSTRY | 3 | Jul 11, 2012 | clinicaltrials |
| NCT00003127 | S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer | completed | Phase 2 | 57 | SWOG Cancer Research NetworkNETWORK | 1 | Jun 14, 2012 | clinicaltrials |
Data updated 23 days agoSource updated Nov 20, 2015source: clinicaltrials